

APPENDIX 17A: pharmacology forest plots


The pharmacological forest plots are referenced 'Pharm xx.xx' in the evidence profiles (appendix 18) and summary evidence profiles in the chapters.

Pharm 01.02 placebo-controlled trials: anger	3
Pharm 01.03 placebo-controlled trials: anger (sensitivity analysis)	3
Pharm 01.04 placebo-controlled trials: anxiety.....	4
Pharm 01.05 placebo-controlled trials: depression	4
Pharm 01.06 placebo-controlled trials: depression (sensitivity analysis)	4
Pharm 01.07 placebo-controlled trials: depression	5
Pharm 01.08 placebo-controlled trials: hostility	5
Pharm 01.09 placebo-controlled trials: hostility (sensitivity analysis)	6
Pharm 01.10 placebo-controlled trials: impulsiveness.....	6
Pharm 01.11 placebo-controlled trials: mental distress	6
Pharm 01.12 placebo-controlled trials: quality of life.....	7
Pharm 01.13 placebo-controlled trials: severe psychopathology.....	7
Pharm 02.01 placebo-controlled trials: leaving treatment early for any reason.....	8
Pharm 02.02 placebo-controlled trials: leaving treatment due to side effects	9
Pharm 02.03 placebo-controlled trials: number reporting side effects	10
Pharm 02.04 placebo-controlled trials: weight change	11
Pharm 02.05 placebo-controlled trials: self-harm (dichotomous data).....	11
Pharm 02.06 placebo-controlled trials: self-harm (continuous data)	11
Pharm 03.01 all available trials: aggression measures (clinician-rated)	12
Pharm 03.02 all available trials: aggression measures (self-rated)	12
Pharm 04.01 all available trials: anger measures (1)	13
Pharm 04.02 all available trials: anger measures (2)	13
Pharm 04.03 all available trials: anger measures (follow-up).....	14
Pharm 05.01 all available trials: anxiety measures (clinician-rated)	14
Pharm 05.02 all available trials: anxiety measures (clinician-rated, follow-up).....	15
Pharm 05.03 all available trials: anxiety measures (self-rated)	15
Pharm 06.01 antidepressants: depression measures (clinician-rated)	16
Pharm 06.02 antidepressants: depression measures (clinician-rated, follow-up)	16
Pharm 06.03 antipsychotics: depression measures (clinician-rated).....	16
Pharm 06.04 antipsychotics: depression measures (clinician-rated).....	17
Pharm 06.05 antipsychotics: depression measures (clinician-rated, follow-up).....	17
Pharm 06.06 anticonvulsants: depression measures (clinician-rated).....	18
Pharm 06.07 omega-3 fatty acids: depression measures (clinician-rated)	18
Pharm 06.08 drug combinations: depression measures (clinician-rated).....	18
Pharm 07.01 antidepressants: depression measures (self-rated)	19
Pharm 07.02 antidepressants: depression measures (self-rated, follow-up)	19
Pharm 07.03 antipsychotics: depression measures (self-rated).....	20
Pharm 07.04 antipsychotics: depression measures (self-rated) (sensitivity analysis).....	20
Pharm 07.05 antipsychotics: depression measures (self-rated).....	21
Pharm 07.06 antipsychotics: depression measures (self-rated, follow-up).....	21
Pharm 07.07 anticonvulsants: depression measures (self-rated).....	21
Pharm 07.08 omega-3 fatty acids: depression measures (self-rated)	22
Pharm 07.09 drug combinations: depression measures (self-rated).....	22

Pharm 08.01 all available trials: global functioning measures.....	22
Pharm 09.01 all available trials: hostility measures (clinician-rated)	23
Pharm 09.02 all available trials: hostility measures (self-rated)	24
Pharm 09.03 antipsychotics: hostility measures (self-rated).....	25
Pharm 09.04 antipsychotics: hostility measures (self-rated) (sensitivity analysis).....	25
Pharm 10.01 all available trials: impulsiveness measures (clinician-rated).....	26
Pharm 10.02 all available trials: impulsiveness measures (self-rated).....	26
Pharm 11.01 all available trials: mental distress	27
Pharm 12.01 all available trials: self-harm/suicidality (dichotomous measures).....	28
Pharm 12.02 all available trials: self-harm/suicidality (continuous measures).....	28
Pharm 13.01 all available trials: severe psychopathology	29
Pharm 14.01 all available trials: BPD symptomatology	29
Pharm 15.01 antidepressants versus placebo: leaving treatment early for any reason.....	30
Pharm 15.02 antidepressants (non-placebo comparisons): leaving treatment early for any reason	30
Pharm 15.03 antipsychotics versus placebo: leaving treatment early for any reason.....	31
Pharm 15.04 antipsychotics versus placebo: leaving treatment early for any reason (sensitivity analysis)...	32
Pharm 15.05 antipsychotics (non-placebo comparisons): leaving treatment early for any reason	32
Pharm 15.06 anticonvulsants versus placebo: leaving treatment early for any reason	33
Pharm 15.07 omega-3 fatty acids: leaving treatment early for any reason	33
Pharm 16.01 antidepressants versus placebo: leaving treatment early due to side effects.....	34
Pharm 16.02 antidepressants (non-placebo comparisons): leaving treatment early due to side effects	34
Pharm 16.03 antipsychotics versus placebo: leaving treatment early due to side effects.....	35
Pharm 16.04 antipsychotics (non-placebo comparisons): leaving treatment early due to side effects.....	36
Pharm 16.05 anticonvulsants versus placebo: leaving treatment early due to side effects.....	37
Pharm 16.06 omega-3 fatty acids versus placebo: leaving treatment early due to side effects.....	38
Pharm 17.01 antidepressants versus placebo: number of participants reporting side effects.....	38
Pharm 17.02 antidepressants (non-placebo comparisons): number of participants reporting side effects....	39
Pharm 17.03 antidepressants versus placebo: number of participants reporting side effects.....	39
Pharm 17.04 antipsychotics versus placebo: number of participants reporting side effects.....	40
Pharm 17.05 anticonvulsants versus placebo: number of participants reporting side effects.....	40
Pharm 17.06 omega-3 fatty acids versus placebo: number of participants reporting side effects.....	41
Pharm 18.01 antidepressants (non-placebo comparisons): weight change	41
Pharm 18.02 antipsychotics: weight change	42
Pharm 18.03 anticonvulsants: weight change	42
Pharm 19.01 sub-analysis by study funding (clinician-rated measures).....	43
Pharm 19.02 sub-analysis by study funding (self-rated measures).....	44


Pharm 01.02 placebo-controlled trials: anger

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 02 Anger




Pharm 01.03 placebo-controlled trials: anger (sensitivity analysis)

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 03 Anger - sensitivity analysis




Pharm 01.04 placebo-controlled trials: anxiety

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 04 Anxiety - insufficient data




Pharm 01.05 placebo-controlled trials: depression

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 05 Depression - clinician-rated




Pharm 01.06 placebo-controlled trials: depression (sensitivity analysis)

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 06 Depression - clinician-rated - sensitivity analysis




Pharm 01.07 placebo-controlled trials: depression

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 07 Depression - self-rated




Pharm 01.08 placebo-controlled trials: hostility

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 08 Hostility




Pharm 01.09 placebo-controlled trials: hostility (sensitivity analysis)

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 09 Hostility - sensitivity analysis




Pharm 01.10 placebo-controlled trials: impulsiveness

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 10 Impulsiveness




Pharm 01.11 placebo-controlled trials: mental distress

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 11 Mental distress




Pharm 01.12 placebo-controlled trials: quality of life

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 12 Quality of life - insufficient data




Pharm 01.13 placebo-controlled trials: severe psychopathology

Review: BPD pharmacology
 Comparison: 01 Placebo-controlled trials - efficacy data
 Outcome: 13 Severe psychopathology (insufficient data)




Pharm 02.01 placebo-controlled trials: leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 02 Placebo-controlled trials - acceptability/tolerability data
 Outcome: 01 Leaving treatment early for any reason




Pharm 02.02 placebo-controlled trials: leaving treatment due to side effects

Review: BPD pharmacology
 Comparison: 02 Placebo-controlled trials - acceptability/tolerability data
 Outcome: 02 Leaving treatment due to side effects




Pharm 02.03 placebo-controlled trials: number reporting side effects

Review: BPD pharmacology
 Comparison: 02 Placebo-controlled trials - acceptability/tolerability data
 Outcome: 03 Number reporting side effects




Pharm 02.04 placebo-controlled trials: weight change

Review: BPD pharmacology
 Comparison: 02 Placebo-controlled trials - acceptability/tolerability data
 Outcome: 04 Weight




Pharm 02.05 placebo-controlled trials: self-harm (dichotomous data)

Review: BPD pharmacology
 Comparison: 02 Placebo-controlled trials - acceptability/tolerability data
 Outcome: 05 Self-harm




Pharm 02.06 placebo-controlled trials: self-harm (continuous data)

Review: BPD pharmacology
 Comparison: 02 Placebo-controlled trials - acceptability/tolerability data
 Outcome: 06 Self-harm (continuous data)




Pharm 03.01 all available trials: aggression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 03 Aggression measures
 Outcome: 01 Clinician-rated measures




Pharm 03.02 all available trials: aggression measures (self-rated)

Review: BPD pharmacology
 Comparison: 03 Aggression measures
 Outcome: 02 Self-rated measures




Pharm 04.01 all available trials: anger measures (1)

Review: BPD pharmacology
 Comparison: 04 Anger measures
 Outcome: 01 STAXI - state anger subscale (8 weeks)




Pharm 04.02 all available trials: anger measures (2)

Review: BPD pharmacology
 Comparison: 04 Anger measures
 Outcome: 02 ZAN-BPD intense anger item




Pharm 04.03 all available trials: anger measures (follow-up)

Review: BPD pharmacology
 Comparison: 04 Anger measures
 Outcome: 03 STAXI - state anger subscale (follow-up)




Pharm 05.01 all available trials: anxiety measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 05 Anxiety measures
 Outcome: 01 Clinician-rated measures (endpoint)




Pharm 05.02 all available trials: anxiety measures (clinician-rated, follow-up)

Review: BPD pharmacology
 Comparison: 05 Anxiety measures
 Outcome: 02 Clinician-rated measures (follow-up)




Pharm 05.03 all available trials: anxiety measures (self-rated)

Review: BPD pharmacology
 Comparison: 05 Anxiety measures
 Outcome: 03 Self-rated measures




Pharm 06.01 antidepressants: depression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 01 Clinician-rated measures (endpoint): antidepressants




Pharm 06.02 antidepressants: depression measures (clinician-rated, follow-up)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 02 Clinician-rated measures (follow-up): antidepressants




Pharm 06.03 antipsychotics: depression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 03 Clinician-rated measures (endpoint): antipsychotics




Pharm 06.04 antipsychotics: depression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 04 Sensitivity analysis: Clinician-rated measures (endpoint): antipsychotics




Pharm 06.05 antipsychotics: depression measures (clinician-rated, follow-up)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 05 Clinician-rated measures (follow-up): antipsychotics




Pharm 06.06 anticonvulsants: depression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 06 Clinician-rated measures (endpoint): anticonvulsants




Pharm 06.07 omega-3 fatty acids: depression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 07 Clinician-rated measures (endpoint): omega-3 fatty acids




Pharm 06.08 drug combinations: depression measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 06 Depression measures: clinician-rated
 Outcome: 08 Clinician-rated measures (endpoint): combination treatments




Pharm 07.01 antidepressants: depression measures (self-rated)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 01 Self-rated measures (endpoint): antidepressants




Pharm 07.02 antidepressants: depression measures (self-rated, follow-up)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 02 Self-rated measures (follow-up): antidepressants




Pharm 07.03 antipsychotics: depression measures (self-rated)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 03 Self-rated measures (endpoint): antipsychotics




Pharm 07.04 antipsychotics: depression measures (self-rated) (sensitivity analysis)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 04 Sensitivity analysis: Self-rated measures (endpoint): antipsychotics




Pharm 07.05 antipsychotics: depression measures (self-rated)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 05 Self-rated measures (endpoint change scores): antipsychotics




Pharm 07.06 antipsychotics: depression measures (self-rated, follow-up)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 06 Self-rated measures (follow-up): antipsychotics




Pharm 07.07 anticonvulsants: depression measures (self-rated)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 07 Self-rated measures (endpoint): anticonvulsants




Pharm 07.08 omega-3 fatty acids: depression measures (self-rated)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 08 Self-rated measures (endpoint): omega-3 fatty acids




Pharm 07.09 drug combinations: depression measures (self-rated)

Review: BPD pharmacology
 Comparison: 07 Depression measures: self-rated
 Outcome: 09 Self-rated measures (endpoint): combination treatments




Pharm 08.01 all available trials: global functioning measures

Review: BPD pharmacology
 Comparison: 08 Global functioning measures
 Outcome: 01 GAS/GAF




Pharm 09.01 all available trials: hostility measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 09 Hostility measures
 Outcome: 01 Clinician-rated measure: Buss-Durkee hostility inventory




Pharm 09.02 all available trials: hostility measures (self-rated)

Review: BPD pharmacology
 Comparison: 09 Hostility measures
 Outcome: 02 Self-complete measure: SCL-90 hostility subscale (some T-scores)




Pharm 09.03 antipsychotics: hostility measures (self-rated)

Review: BPD pharmacology
 Comparison: 09 Hostility measures
 Outcome: 03 Self-complete measure: SCL-90 hostility subscale (antipsychotics) some T-scores




Pharm 09.04 antipsychotics: hostility measures (self-rated) (sensitivity analysis)

Review: BPD pharmacology
 Comparison: 09 Hostility measures
 Outcome: 04 Sensitivity analysis: Self-complete measure: SCL-90 hostility subscale (antipsychotics) some T-scores




Pharm 10.01 all available trials: impulsiveness measures (clinician-rated)

Review: BPD pharmacology
 Comparison: 10 Impulsiveness measures
 Outcome: 01 Clinician-rated measure: Barratt Impulsiveness Scale




Pharm 10.02 all available trials: impulsiveness measures (self-rated)

Review: BPD pharmacology
 Comparison: 10 Impulsiveness measures
 Outcome: 02 Self-rated measure: STIC




Pharm 11.01 all available trials: mental distress

Review: BPD pharmacology
 Comparison: 11 Mental distress
 Outcome: 01 GSI




Pharm 12.01 all available trials: self-harm/suicidality (dichotomous measures)

Review: BPD pharmacology
 Comparison: 12 Self-harm/suicidality
 Outcome: 01 Number of participants (8/12 weeks)




Pharm 12.02 all available trials: self-harm/suicidality (continuous measures)

Review: BPD pharmacology
 Comparison: 12 Self-harm/suicidality
 Outcome: 02 Self-harm/suicidality continuous measures




Pharm 13.01 all available trials: severe psychopathology

Review: BPD pharmacology
 Comparison: 13 Severe psychopathology
 Outcome: 01 BPRS




Pharm 14.01 all available trials: BPD symptomatology

Review: BPD pharmacology
 Comparison: 14 BPD symptomatology
 Outcome: 01 ZAN-BPD




Pharm 15.01 antidepressants versus placebo: leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 01 Antidepressants vs placebo




Pharm 15.02 antidepressants (non-placebo comparisons): leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 02 Antidepressants (non-placebo comparisons)




Pharm 15.03 antipsychotics versus placebo: leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 03 Antipsychotics vs placebo




Pharm 15.04 antipsychotics vs placebo leaving treatment early for any reason (sensitivity analysis)

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 04 Antipsychotics vs placebo (sensitivity analysis)




Pharm 15.05 antipsychotics (non-placebo comparisons): leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 05 Antipsychotics (non-placebo comparisons)




Pharm 15.06 anticonvulsants vs placebo: leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 06 Anticonvulsants vs placebo




Pharm 15.07 omega-3 fatty acids: leaving treatment early for any reason

Review: BPD pharmacology
 Comparison: 15 Leaving treatment early for any reason
 Outcome: 07 Other




Pharm 16.01 antidepressants versus placebo: leaving treatment early due to side effects

Review: BPD pharmacology
 Comparison: 16 Leaving treatment early due to side effects
 Outcome: 01 Antidepressants versus placebo




Pharm 16.02 antidepressants (non-placebo comparisons): leaving treatment early due to side effects

Review: BPD pharmacology
 Comparison: 16 Leaving treatment early due to side effects
 Outcome: 02 Antidepressants (non-placebo comparisons)




Pharm 16.03 antipsychotics versus placebo: leaving treatment early due to side effects

Review: BPD pharmacology
 Comparison: 16 Leaving treatment early due to side effects
 Outcome: 03 Antipsychotics versus placebo




Pharm 16.04 antipsychotics (non-placebo comparisons): leaving treatment early due to side effects

Review: BPD pharmacology
 Comparison: 16 Leaving treatment early due to side effects
 Outcome: 04 Antipsychotics (non-placebo comparisons)




Pharm 16.05 anticonvulsants versus placebo: leaving treatment early due to side effects

Review: BPD pharmacology
 Comparison: 16 Leaving treatment early due to side effects
 Outcome: 05 Anticonvulsants vs placebo




Pharm 16.06 omega-3 fatty acids versus placebo: leaving treatment early due to side effects

Review: BPD pharmacology
 Comparison: 16 Leaving treatment early due to side effects
 Outcome: 06 Other




Pharm 17.01 antidepressants versus placebo: number of participants reporting side effects

Review: BPD pharmacology
 Comparison: 17 Number of participants reporting side effects
 Outcome: 01 Antidepressants vs placebo




Pharm 17.02 antidepressants (non-placebo comparisons): number of participants reporting side effects

Review: BPD pharmacology
 Comparison: 17 Number of participants reporting side effects
 Outcome: 02 Antidepressants (non-placebo comparisons)




Pharm 17.03 antidepressants versus placebo: number of participants reporting side effects

Review: BPD pharmacology
 Comparison: 17 Number of participants reporting side effects
 Outcome: 03 Antipsychotics vs placebo




Pharm 17.04 antipsychotics versus placebo: number of participants reporting side effects

Review: BPD pharmacology
 Comparison: 17 Number of participants reporting side effects
 Outcome: 04 Antipsychotics (non-placebo comparisons)




Pharm 17.05 anticonvulsants versus placebo: number of participants reporting side effects

Review: BPD pharmacology
 Comparison: 17 Number of participants reporting side effects
 Outcome: 05 Anticonvulsants vs placebo




Pharm 17.06 omega-3 fatty acids versus placebo: number of participants reporting side effects

Review: BPD pharmacology
 Comparison: 17 Number of participants reporting side effects
 Outcome: 06 Other




Pharm 18.01 antidepressants (non-placebo comparisons): weight change

Review: BPD pharmacology
 Comparison: 18 Side effects: weight or weight change (kg)
 Outcome: 01 Antidepressants




Pharm 18.02 antipsychotics: weight change

Review: BPD pharmacology
 Comparison: 18 Side effects: weight or weight change (kg)
 Outcome: 02 Antipsychotics




Pharm 18.03 anticonvulsants: weight change

Review: BPD pharmacology
 Comparison: 18 Side effects: weight or weight change (kg)
 Outcome: 03 Anticonvulsants



Pharm 19.01 sub-analysis by study funding (clinician-rated measures)

Review: BPD pharmacology
 Comparison: 19 Sub-analysis by study funding
 Outcome: 01 Single active treatment vs placebo: clinician-rated efficacy measure(s) (combined)



Pharm 19.02 sub-analysis by study funding (self-rated measures)

Review: BPD pharmacology
 Comparison: 19 Sub-analysis by study funding
 Outcome: 02 Single active treatment vs placebo: Self-rated efficacy measure(s) (combined)

